Q-omics provides the consensus-scored RPL9P18 profile across patient tissues and cancer cell-line models. RPL9P18 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL9P18 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RPL9P18 RNA expression shows 13,388 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where RPL9P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL9P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL9P18 survival associations across molecular data types. RPL9P18 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL9P18 RNA expression–survival associations across cancer types. High RPL9P18 expression shows unfavorable associations in ACC, LIHC, OV and UCEC, but favorable associations in SKCM and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL9P18 RNA expression.
This table summarizes RPL9P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL9P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL9P18 shows lower tumor expression in UCEC, BRCA and STAD and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher RPL9P18 RNA expression in tumor versus normal tissue (log2 FC = +0.245, t-test p < 0.001).
This table shows molecular features associated with RPL9P18 in patient tissues and cancer cell lines. In patient samples, RPL9P18 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
